Repligen Corp
RGEN
View Detailed Chart
120.230USD
+1.540+1.30%
Close 09/10, 16:00（ET）Quotes delayed by 15 min
6.76BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.30%
5 Days
+3.49%
1 Month
+7.90%
6 Months
-12.23%
Year to Date
-16.47%
1 Year
-18.04%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
22
analysts
Buy
Current Rating
180.013
Target Price
+49.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 25.51M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -650.91, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 61.98M shares, decreasing 4.93% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 5.07M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Ticker SymbolRGEN
CompanyRepligen Corp
CEOMr. Olivier Loeillot
Websitehttps://www.repligen.com/
Related Instruments
-1.96%
-2.49%
-1.86%
-0.79%
-1.08%
-2.69%
-1.31%
-3.06%
-1.84%
-4.31%
-1.49%
+1.26%
-1.91%
-0.86%
-2.30%
-1.92%
-5.26%
-2.20%
-0.35%
-1.55%
